Quick Answer
Vivos Therapeutics, Inc. reported Stockholders Equity of $7.95 million for fiscal year 2024.
Vivos Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $7.95M | +1835.3% |
| 2023 | $411.0K | -91.4% |
| 2022 | $4.80M | -81.2% |
| 2021 | $25.54M | +51.0% |
| 2020 | $16.92M | +674.8% |
| 2019 | -$2.94M | -161.0% |
| 2018 | $4.83M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.53M | -67.0% | -44.8% |
| June 30, 2025 | $4.58M | -27.8% | +4.0% |
| March 31, 2025 | $4.41M | +657.2% | -44.6% |
| December 31, 2024 | $7.95M | +1835.3% | +3.8% |
| September 30, 2024 | $7.67M | +16563.0% | +20.8% |
| June 30, 2024 | $6.35M | +201.4% | +990.5% |
| March 31, 2024 | $582.0K | -91.7% | +41.6% |
| December 31, 2023 | $411.0K | -91.4% | +793.5% |
- Vivos Therapeutics, Inc. showed an increase of +1835.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2024 period, Vivos Therapeutics, Inc.’s stockholders equity has grown by 64.8% (from $4.83 million to $7.95 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: